443
Total Publications
28,606
Total Citations
Top Researchers
- Young‐Jin Kim 13,973 citations • 733 papers
- B. Gillot 2,526 citations • 167 papers
- Jean‐François Denef 2,187 citations • 99 papers
- Nathan Vastesaeger 2,157 citations • 68 papers
- Katrien Venken 1,834 citations • 47 papers
- M. De Smet 1,453 citations • 54 papers
- André Bento‐Abreu 1,147 citations • 22 papers
- Stéphanie Coulon 1,133 citations • 40 papers
- Tine Van de Sande 1,054 citations • 12 papers
- Saar Vandekeere 1,029 citations • 8 papers
Most Cited Papers
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater 2019 • 1,685 citations
- Amiloride and its analogs as tools in the study of ion transport 1988 • 1,141 citations
- Alendronate for the Treatment of Osteoporosis in Men 2000 • 974 citations
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 2020 • 637 citations
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study 1999 • 594 citations
- Understanding modern-day vaccines: what you need to know 2017 • 349 citations
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density 2009 • 330 citations
- [<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for<i>in vivo</i>human PET brain imaging of the cannabinoid-1 receptor 2007 • 314 citations
- Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence 2022 • 262 citations
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect 2010 • 246 citations